AstraZeneca dual immunotherapy approved for US liver cancer patients
The FDA has approved Imfinzi™ combined with Imjudo for adults with unresectable liver cancer, based on a lower risk of death compared to only sorafenib.
List view / Grid view
The FDA has approved Imfinzi™ combined with Imjudo for adults with unresectable liver cancer, based on a lower risk of death compared to only sorafenib.
In its latest meeting, the Committee for Medicinal Products for Human Use (CHMP) recommended 12 medicines for approval, including those for rare diseases, osteoporosis and cancer.
Imfinzi (durvalumab) demonstrated a meaningful overall survival (OS) benefit versus sorafenib as a first-line treatment for liver cancer.
NICE has issued its final appraisal decision recommending reimbursement of Lenvima for the treatment of progressive, locally advanced or metastatic, differentiated thyroid carcinoma...
In vitro study verifies method for remotely triggering release of cancer drugs...
Breast cancer drug neratinib has been found to block the function of the Ras genes which are among the first to be linked to cancer development...
NICE has recommended sorafenib to be routinely available for patients on the NHS making it one of the 24 drugs appraised from the CDF...
NICE has released a Final Appraisal Document recommending Nexavar for the treatment of patients with advanced hepatocellular carcinoma...
Bayer have announced the European Commission has granted marketing authorisation for Stivarga...